Tag: Novo Nordisk

As global regulators flag shortages involving semaglutide in injectable and oral versions, there are concerns whether the impact could spill over into India as well. Novo Nordisk’s oral semaglutide (Rybelsus), touted to be a game-changer in treating Type 2 diabetes, was launched early last year in India. The pill is marketed in three strengths (3, 7 and 14 mg), and is finding takers despite its high price (about Rs 10,000 a month), diabetologists said. However, patients are finding that Rybelsus is sometimes out of stock in a particular strength,...